WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206443

CAS#: 870964-67-3

Description: Evocalcet is a calcium-sensing receptor agonist. The calcium-sensing receptor (CaSR) is a Class C G-protein coupled receptor which senses extracellular levels of calcium ion. The calcium-sensing receptor controls calcium homeostasis by regulating the release of parathyroid hormone (PTH). CaSR is expressed in all of the organs of the digestive system. CaSR plays a key role in gastrointestinal physiological function and in the occurrence of digestive disease. High dietary Ca2+ may stimulate CaSR activation and could both inhibit tumor development and increase the chemotherapeutic sensitivity of cancer cells in colon cancer tissues.

Chemical Structure

CAS# 870964-67-3

Theoretical Analysis

MedKoo Cat#: 206443
Name: Evocalcet
CAS#: 870964-67-3
Chemical Formula: C24H26N2O2
Exact Mass: 374.19943
Molecular Weight: 374.48
Elemental Analysis: C, 76.98; H, 7.00; N, 7.48; O, 8.54

Price and Availability

Size Price Availability Quantity
1.0mg USD 230.0 2 Weeks
5.0mg USD 500.0 2 Weeks
10.0mg USD 770.0 2 Weeks
25.0mg USD 1260.0 2 Weeks
Bulk inquiry

Synonym: MT-4580; MT 4580; MT4580; KHK-7580; KHK7580; KHK 7580; Evocalcet;

IUPAC/Chemical Name: 2-(4-((S)-3-(((R)-1-(naphthalen-1-yl)ethyl)amino)pyrrolidin-1-yl)phenyl)acetic acid


InChi Code: InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1

SMILES Code: O=C(O)CC1=CC=C(N2C[C@@H](N[C@@H](C3=C4C=CC=CC4=CC=C3)C)CC2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMF 5.0
DMSO 5.0
DMSO:PBS (pH 7.2) (1:2) 0.3

Preparing Stock Solutions

The following data is based on the product molecular weight 374.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial. 2019 Sep 5;24(3):248–57. doi: 10.1111/1744-9987.13434. Epub ahead of print. PMID: 31486206; PMCID: PMC7317959.

2: Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. doi: 10.1371/journal.pone.0232428. PMID: 32343734; PMCID: PMC7188245.

3: Parfrey PS. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. Kidney Int. 2018 Oct;94(4):661-662. doi: 10.1016/j.kint.2018.06.022. PMID: 30243312.

4: Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018 Oct;94(4):818-825. doi: 10.1016/j.kint.2018.05.013. Epub 2018 Jul 24. PMID: 30049473.

5: Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Exp Nephrol. 2019 Feb;23(2):258-267. doi: 10.1007/s10157-018-1635-6. Epub 2018 Aug 29. PMID: 30159688; PMCID: PMC6510802.

6: Tokunaga S, Endo Y, Kawata T. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)]. Nihon Yakurigaku Zasshi. 2019;154(1):35-43. Japanese. doi: 10.1254/fpj.154.35. PMID: 31308348.

7: Hamano N, Endo Y, Kawata T, Fukagawa M. Development of evocalcet for unmet needs among calcimimetic agents. Expert Rev Endocrinol Metab. 2020 Sep;15(5):299-310. doi: 10.1080/17446651.2020.1780911. Epub 2020 Jun 18. PMID: 32552012.

8: Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019 Jun;23(6):739-748. doi: 10.1007/s10157-019-01692-y. Epub 2019 Apr 6. Erratum in: Clin Exp Nephrol. 2019 Jul 5;: PMID: 30955188; PMCID: PMC6586709.

9: Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol. 2018 Sep 11;10:101-111. doi: 10.2147/CPAA.S171044. PMID: 30254496; PMCID: PMC6141109.

10: Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Long- Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Sci Rep. 2019 Apr 23;9(1):6410. doi: 10.1038/s41598-019-42017-z. PMID: 31015494; PMCID: PMC6478860.

11: Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab. 2020 Sep;38(5):687-694. doi: 10.1007/s00774-020-01097-y. Epub 2020 Apr 9. PMID: 32274572.

12: Akizawa T, Shimazaki R, Fukagawa M; Evocalcet Study Group. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One. 2018 Oct 31;13(10):e0204896. doi: 10.1371/journal.pone.0204896. PMID: 30379826; PMCID: PMC6209414.

13: Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. PMID: 29614098; PMCID: PMC5882164.

14: Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg Med Chem Lett. 2018 Jun 15;28(11):2055-2060. doi: 10.1016/j.bmcl.2018.04.055. Epub 2018 Apr 24. PMID: 29724589.

15: Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019 Sep;23(9):1173. doi: 10.1007/s10157-019-01758-x. Erratum for: Clin Exp Nephrol. 2019 Jun;23(6):739-748. PMID: 31278658; PMCID: PMC6828059.

16: Xie J, Li X, Chen Y, Chen M, Mao N, Fan J. Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020 Nov 13;99(46):e22566. doi: 10.1097/MD.0000000000022566. PMID: 33181644; PMCID: PMC7668479.

17: Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R, Fukagawa M, Akizawa T. Assessment of CYP- Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clin Transl Sci. 2019 Jan;12(1):20-27. doi: 10.1111/cts.12588. Epub 2018 Oct 24. PMID: 30238620; PMCID: PMC6342237.

18: Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clin Drug Investig. 2018 Oct;38(10):945-954. doi: 10.1007/s40261-018-0687-4. PMID: 30168004; PMCID: PMC6182462.

19: Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T. Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis. Int J Nephrol Renovasc Dis. 2020 May 12;13:97-106. doi: 10.2147/IJNRD.S243210. PMID: 32494184; PMCID: PMC7229806.

20: Srinivas NR. Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in- Human Phase I Study. Clin Drug Investig. 2019 Jan;39(1):105-107. doi: 10.1007/s40261-018-0738-x. PMID: 30632108.